Details of the Drug

General Information of Drug (ID: DM7RJXL)

Drug Name
Imatinib
Synonyms
Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1], [2]
Chronic myelogenous leukaemia 2A20.0 Approved [3], [4]
Intestinal cancer 2C0Z Phase 3 [3], [4]
Lung cancer 2C25.0 Phase 2 [3], [4]
Systemic mastocytosis 2A21.0 Investigative [5]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 493.6
Topological Polar Surface Area (xlogp) 3.5
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [6]
Bioavailability
98% of drug becomes completely available to its intended biological destination(s) [7]
Clearance
The drug present in the plasma can be removed from the body at the rate of 3.3 mL/min/kg [8]
Elimination
5% of drug is excreted from urine in the unchanged form [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 22 hours [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 20.25863 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.05% [8]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.9 L/kg [8]
Water Solubility
The ability of drug to dissolve in water is measured as 1 mg/mL [6]
Chemical Identifiers
Formula
C29H31N7O
IUPAC Name
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
Canonical SMILES
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
InChI
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
InChIKey
KTUFNOKKBVMGRW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5291
ChEBI ID
CHEBI:45783
CAS Number
152459-95-5
DrugBank ID
DB00619
TTD ID
D0AZ3C
VARIDT ID
DR00032
INTEDE ID
DR0858
ACDINA ID
D00324

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Inhibitor [10]
Mcl-1 messenger RNA (MCL-1 mRNA) TTN6ORK MCL1_HUMAN Not Available [5]
Platelet-derived growth factor receptor (PDGFR) TTI2WET NOUNIPROTAC Inhibitor [10]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Inhibitor [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [11]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [12]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [13]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [14]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [14]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [15]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [16]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [17]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [18]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [19]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [20]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [21]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [22]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Lung tissue
The Studied Disease Lung cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosine-protein kinase Kit (KIT) DTT KIT 2.26E-22 -0.78 -1.33
P-glycoprotein 1 (ABCB1) DTP P-GP 3.12E-33 -8.30E-01 -1.04E+00
Organic cation transporter 1 (SLC22A1) DTP SLC22A1 1.45E-02 -7.93E-02 -2.43E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 3.87E-47 -1.28E+00 -1.63E+00
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTP OATP1A2 1.86E-09 -2.50E-01 -3.86E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 3.46E-61 1.83E-01 7.90E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 2.80E-34 1.44E-01 9.71E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 5.28E-05 1.90E-02 1.09E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 5.52E-19 -2.25E-01 -5.53E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.12E-38 -1.81E+00 -2.01E+00
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 1.76E-04 -4.73E-02 -2.39E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.08E-03 1.76E-02 7.09E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.59E-39 -3.76E-01 -1.64E+00
Prostaglandin G/H synthase 1 (COX-1) DME PTGS1 2.29E-28 -5.62E-01 -1.35E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Imatinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Imatinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [148]
Nilotinib DM7HXWT Moderate Decreased metabolism of Imatinib caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [149]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Imatinib caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [150]
Dasatinib DMJV2EK Moderate Decreased metabolism of Imatinib caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [151]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Imatinib and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [152]
Coadministration of a Drug Treating the Disease Different from Imatinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [153]
Tretinoin DM49DUI Moderate Decreased metabolism of Imatinib caused by Tretinoin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [154]
Metreleptin DM1NOEK Moderate Increased metabolism of Imatinib caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [155]
Repaglinide DM5SXUV Moderate Decreased metabolism of Imatinib caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [156]
Pioglitazone DMKJ485 Moderate Decreased metabolism of Imatinib caused by Pioglitazone mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [148]
Nateglinide DMLK2QH Moderate Decreased metabolism of Imatinib caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [157]
Ivosidenib DM8S6T7 Major Increased metabolism of Imatinib caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [158]
Midostaurin DMI6E0R Moderate Decreased metabolism of Imatinib caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [159]
Arn-509 DMT81LZ Major Increased metabolism of Imatinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [155]
Gilteritinib DMWQ4MZ Moderate Decreased metabolism of Imatinib caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [150]
Oliceridine DM6MDCF Major Decreased metabolism of Imatinib caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [160]
Mitotane DMU1GX0 Major Increased metabolism of Imatinib caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [155]
Donepezil DMIYG7Z Minor Decreased metabolism of Imatinib caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [161]
Ivabradine DM0L594 Major Decreased metabolism of Imatinib caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [150]
Bepridil DM0RKS4 Moderate Decreased metabolism of Imatinib caused by Bepridil mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [148]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Imatinib caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [162]
Nifedipine DMSVOZT Moderate Decreased metabolism of Imatinib caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [148]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [163]
Clorazepate DMC3JST Moderate Decreased metabolism of Imatinib caused by Clorazepate mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [153]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Imatinib caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [155]
Posaconazole DMUL5EW Moderate Decreased metabolism of Imatinib caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [148]
Budesonide DMJIBAW Moderate Decreased metabolism of Imatinib caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [164]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Imatinib and Roflumilast. Asthma [CA23] [150]
Zileuton DMVRIC2 Moderate Decreased metabolism of Imatinib caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [148]
Oritavancin DM28D05 Moderate Increased metabolism of Imatinib caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [155]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Imatinib caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [153]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Imatinib caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [148]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Imatinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [148]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Imatinib caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [165]
Ag-221 DMS0ZBI Moderate Decreased clearance of Imatinib due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [153]
Cariprazine DMJYDVK Moderate Decreased metabolism of Imatinib caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [166]
Erdafitinib DMI782S Moderate Decreased clearance of Imatinib due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [167]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Imatinib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [168]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Imatinib caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [169]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Imatinib caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [170]
HKI-272 DM6QOVN Major Decreased metabolism of Imatinib caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [171]
LY2835219 DM93VBZ Moderate Decreased metabolism of Imatinib caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [172]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Imatinib caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [148]
Tucatinib DMBESUA Moderate Decreased metabolism of Imatinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [148]
Tamoxifen DMLB0EZ Moderate Decreased metabolism of Imatinib caused by Tamoxifen mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [148]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Imatinib caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [173]
Bosutinib DMTI8YE Major Decreased metabolism of Imatinib caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [153]
Estradiol DMUNTE3 Moderate Decreased metabolism of Imatinib caused by Estradiol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [148]
Atorvastatin DMF28YC Moderate Decreased metabolism of Imatinib caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [174]
Macitentan DMP79A1 Moderate Decreased metabolism of Imatinib caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [175]
PF-04449913 DMSB068 Moderate Decreased metabolism of Imatinib caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [176]
Indacaterol DMQJHR7 Minor Decreased metabolism of Imatinib caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [177]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Imatinib caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [155]
Dihydrocodeine DMB0FWL Moderate Decreased metabolism of Imatinib caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [153]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Imatinib caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [178]
Ulipristal DMBNI20 Minor Decreased metabolism of Imatinib caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [150]
Mestranol DMG3F94 Moderate Decreased metabolism of Imatinib caused by Mestranol mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [153]
Levobupivacaine DM783CH Moderate Decreased metabolism of Imatinib caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [150]
Cocaine DMSOX7I Moderate Decreased metabolism of Imatinib caused by Cocaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [153]
Alfentanil DMVO0UB Major Decreased metabolism of Imatinib caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [179]
Mifepristone DMGZQEF Moderate Decreased metabolism of Imatinib caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [180]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Imatinib caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [150]
Ivacaftor DMZC1HS Major Decreased metabolism of Imatinib caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [150]
MK-8228 DMOB58Q Moderate Decreased metabolism of Imatinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [148]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Imatinib caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [153]
Aprepitant DM053KT Moderate Decreased metabolism of Imatinib caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [181]
Sertraline DM0FB1J Moderate Decreased metabolism of Imatinib caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [148]
Trimipramine DM1SC8M Moderate Decreased metabolism of Imatinib caused by Trimipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [148]
Vilazodone DM4LECQ Moderate Decreased metabolism of Imatinib caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [182]
Paroxetine DM5PVQE Moderate Decreased metabolism of Imatinib caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [148]
Escitalopram DMFK9HG Minor Decreased metabolism of Imatinib caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [183]
Desvenlafaxine DMHD4PE Moderate Decreased metabolism of Imatinib caused by Desvenlafaxine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [148]
OPC-34712 DMHG57U Major Decreased metabolism of Imatinib caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [184]
Clomipramine DMINRKW Moderate Decreased metabolism of Imatinib caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [148]
Trazodone DMK1GBJ Moderate Decreased metabolism of Imatinib caused by Trazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [148]
Doxepin DMPI98T Moderate Decreased metabolism of Imatinib caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [148]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Imatinib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [185]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Imatinib caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [153]
Ospemifene DMC4GEI Moderate Decreased metabolism of Imatinib caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [186]
Diazepam DM08E9O Moderate Decreased metabolism of Imatinib caused by Diazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [148]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Imatinib caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [148]
Primidone DM0WX6I Major Increased metabolism of Imatinib caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [155]
Felbamate DM1V5ZS Moderate Increased metabolism of Imatinib caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [155]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Imatinib caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [155]
Cenobamate DMGOVHA Moderate Increased metabolism of Imatinib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [155]
Tiagabine DMKSQG0 Moderate Decreased metabolism of Imatinib caused by Tiagabine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [148]
Stiripentol DMMSDOY Moderate Decreased metabolism of Imatinib caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [150]
Fosphenytoin DMOX3LB Major Increased metabolism of Imatinib caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [155]
Clonazepam DMTO13J Moderate Decreased metabolism of Imatinib caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [148]
Lacosamide DMVM6QR Moderate Decreased metabolism of Imatinib caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [153]
Rufinamide DMWE60C Moderate Increased metabolism of Imatinib caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [155]
Phenobarbital DMXZOCG Major Increased metabolism of Imatinib caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [155]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Imatinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [155]
Cannabidiol DM0659E Minor Decreased metabolism of Imatinib caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [150]
Nicardipine DMCDYW7 Moderate Decreased metabolism of Imatinib caused by Nicardipine mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [148]
Mefenamic acid DMK7HFI Moderate Decreased metabolism of Imatinib caused by Mefenamic acid mediated inhibition of CYP450 enzyme. Female pelvic pain [GA34] [148]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Imatinib caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [187]
Tazemetostat DMWP1BH Major Decreased metabolism of Imatinib caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [188]
Solifenacin DMG592Q Moderate Decreased metabolism of Imatinib caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [189]
Mirabegron DMS1GYT Minor Decreased metabolism of Imatinib caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [190]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Imatinib caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [191]
Itraconazole DMCR1MV Moderate Decreased metabolism of Imatinib caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [148]
Miconazole DMPMYE8 Moderate Decreased metabolism of Imatinib caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [148]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Imatinib caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [192]
Dexlansoprazole DM1DBV5 Moderate Decreased metabolism of Imatinib caused by Dexlansoprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [193]
Ripretinib DM958QB Moderate Decreased metabolism of Imatinib caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [153]
Avapritinib DMK2GZX Major Decreased metabolism of Imatinib caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [150]
Colchicine DM2POTE Major Decreased metabolism of Imatinib caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [194]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Imatinib caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [155]
Ergotamine DMKR3C5 Moderate Decreased metabolism of Imatinib caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [195]
Eplerenone DMF0NQR Major Decreased metabolism of Imatinib caused by Eplerenone mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [196]
Carvedilol DMHTEAO Moderate Decreased metabolism of Imatinib caused by Carvedilol mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [148]
Boceprevir DMBSHMF Moderate Decreased metabolism of Imatinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [148]
Telaprevir DMMRV29 Moderate Decreased metabolism of Imatinib caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [148]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Imatinib caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [153]
Rifampin DMA8J1G Major Increased metabolism of Imatinib caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [155]
Rifapentine DMCHV4I Major Increased metabolism of Imatinib caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [155]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [197]
MK-1439 DM215WE Minor Decreased metabolism of Imatinib caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [198]
Delavirdine DM3NF5G Moderate Decreased metabolism of Imatinib caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [148]
Fostemsavir DM50ILT Moderate Decreased clearance of Imatinib due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [199]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Imatinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [148]
Efavirenz DMC0GSJ Moderate Decreased metabolism of Imatinib caused by Efavirenz mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [148]
Dolutegravir DMCZGRE Minor Decreased metabolism of Imatinib caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [200]
Saquinavir DMG814N Moderate Decreased metabolism of Imatinib caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [148]
Etravirine DMGV8QU Moderate Decreased metabolism of Imatinib caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [201]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Imatinib caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [153]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Imatinib caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [148]
Atazanavir DMSYRBX Moderate Decreased metabolism of Imatinib caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [202]
Maraviroc DMTL94F Moderate Decreased clearance of Imatinib due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [203]
Simvastatin DM30SGU Moderate Decreased metabolism of Imatinib caused by Simvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [174]
Fluvastatin DM4MDJY Moderate Decreased metabolism of Imatinib caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [153]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Imatinib and Mipomersen. Hyper-lipoproteinaemia [5C80] [204]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Imatinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [205]
BMS-201038 DMQTAGO Major Decreased metabolism of Imatinib caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [153]
Aliskiren DM1BV7W Moderate Decreased clearance of Imatinib due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [178]
Losartan DM72JXH Moderate Decreased metabolism of Imatinib caused by Losartan mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [148]
Nebivolol DM7F1PA Moderate Decreased metabolism of Imatinib caused by Nebivolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [148]
Levamlodipine DM92S6N Moderate Decreased metabolism of Imatinib caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [178]
Verapamil DMA7PEW Moderate Decreased metabolism of Imatinib caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [148]
Pindolol DMD2NV7 Moderate Decreased metabolism of Imatinib caused by Pindolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [148]
Conivaptan DM1V329 Moderate Decreased metabolism of Imatinib caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [206]
Tolvaptan DMIWFRL Moderate Decreased metabolism of Imatinib caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [207]
Fludrocortisone DMUDIR8 Moderate Decreased metabolism of Imatinib caused by Fludrocortisone mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [148]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Imatinib caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [150]
Retapamulin DM9JXB7 Minor Decreased metabolism of Imatinib caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [208]
Lesinurad DMUR64T Moderate Decreased metabolism of Imatinib caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [209]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Imatinib caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [148]
Suvorexant DM0E6S3 Major Decreased metabolism of Imatinib caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [210]
Amobarbital DM0GQ8N Moderate Increased metabolism of Imatinib caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [155]
Ramelteon DM7IW9J Moderate Decreased metabolism of Imatinib caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [211]
Flurazepam DMAL4G0 Moderate Decreased metabolism of Imatinib caused by Flurazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [148]
Triazolam DMETYK5 Moderate Decreased metabolism of Imatinib caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [148]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Imatinib caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [212]
ITI-007 DMUQ1DO Major Decreased metabolism of Imatinib caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [213]
Estazolam DMZGXUM Moderate Decreased metabolism of Imatinib caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [148]
Pemigatinib DM819JF Major Decreased metabolism of Imatinib caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [150]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Imatinib caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [155]
Testosterone DM7HUNW Moderate Decreased metabolism of Imatinib caused by Testosterone mediated inhibition of CYP450 enzyme. Low bone mass disorder [FB83] [148]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Imatinib and Denosumab. Low bone mass disorder [FB83] [214]
Crizotinib DM4F29C Moderate Decreased metabolism of Imatinib caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [148]
Brigatinib DM7W94S Major Decreased metabolism of Imatinib caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [153]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Imatinib and Porfimer Sodium. Lung cancer [2C25] [215]
Ceritinib DMB920Z Moderate Decreased metabolism of Imatinib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [216]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Imatinib caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [217]
PF-06463922 DMKM7EW Moderate Decreased metabolism of Imatinib caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [148]
Osimertinib DMRJLAT Moderate Decreased metabolism of Imatinib caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [218]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Imatinib caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [219]
Capmatinib DMYCXKL Moderate Decreased clearance of Imatinib due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [220]
Selpercatinib DMZR15V Major Decreased metabolism of Imatinib caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [150]
Halofantrine DMOMK1V Major Decreased metabolism of Imatinib caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [221]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Imatinib caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [153]
Primaquine DMWQ16I Moderate Decreased metabolism of Imatinib caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [148]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [222]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Idelalisib. Mature B-cell leukaemia [2A82] [223]
GDC-0199 DMH0QKA Major Decreased metabolism of Imatinib caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [153]
IPI-145 DMWA24P Moderate Decreased metabolism of Imatinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [224]
Acalabrutinib DM7GCVW Major Decreased metabolism of Imatinib caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [225]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Clofarabine. Mature B-cell lymphoma [2A85] [226]
Ibrutinib DMHZCPO Major Decreased metabolism of Imatinib caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [227]
Vemurafenib DM62UG5 Moderate Increased metabolism of Imatinib caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [155]
Selumetinib DMC7W6R Major Decreased metabolism of Imatinib caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [228]
LGX818 DMNQXV8 Major Decreased metabolism of Imatinib caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [229]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Imatinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [155]
Estrone DM5T6US Moderate Decreased metabolism of Imatinib caused by Estrone mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [148]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of Imatinib caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [153]
Danazol DML8KTN Moderate Decreased metabolism of Imatinib caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [148]
Ubrogepant DM749I3 Moderate Decreased metabolism of Imatinib caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [230]
Almogran DM7I64Z Moderate Decreased metabolism of Imatinib caused by Almogran mediated inhibition of CYP450 enzyme. Migraine [8A80] [148]
Rimegepant DMHOAUG Moderate Decreased metabolism of Imatinib caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [231]
Lasmiditan DMXLVDT Moderate Decreased clearance of Imatinib due to the transporter inhibition by Lasmiditan. Migraine [8A80] [232]
Exjade DMHPRWG Moderate Decreased metabolism of Imatinib caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [233]
Flibanserin DM70DTN Major Decreased metabolism of Imatinib caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [234]
Midazolam DMXOELT Moderate Decreased metabolism of Imatinib caused by Midazolam mediated inhibition of CYP450 enzyme. Mood/affect symptom [MB24] [148]
Panobinostat DM58WKG Moderate Decreased metabolism of Imatinib caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [235]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Imatinib and Tecfidera. Multiple sclerosis [8A40] [236]
Siponimod DM2R86O Major Decreased metabolism of Imatinib caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [153]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Imatinib and Fingolimod. Multiple sclerosis [8A40] [237]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Imatinib and Ocrelizumab. Multiple sclerosis [8A40] [238]
Deflazacort DMV0RNS Major Decreased metabolism of Imatinib caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [150]
Modafinil DMYILBE Minor Decreased metabolism of Imatinib caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [153]
Promethazine DM6I5GR Moderate Decreased metabolism of Imatinib caused by Promethazine mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [148]
Netupitant DMEKAYI Moderate Decreased metabolism of Imatinib caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [150]
Granisetron DMIUW25 Moderate Decreased metabolism of Imatinib caused by Granisetron mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [148]
Ondansetron DMOTQ1I Moderate Decreased metabolism of Imatinib caused by Ondansetron mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [148]
Entrectinib DMMPTLH Major Decreased metabolism of Imatinib caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [153]
Sibutramine DMFJTDI Minor Decreased metabolism of Imatinib caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [239]
Dexfenfluramine DMJ7YDS Moderate Decreased metabolism of Imatinib caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [148]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Imatinib caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [240]
S-297995 DM26IH8 Moderate Decreased metabolism of Imatinib caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [150]
Naproxen DMZ5RGV Moderate Decreased metabolism of Imatinib caused by Naproxen mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [148]
Olaparib DM8QB1D Major Decreased metabolism of Imatinib caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [153]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Imatinib caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [148]
Ibuprofen DM8VCBE Moderate Decreased metabolism of Imatinib caused by Ibuprofen mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [148]
Methamphetamine DMPM4SK Moderate Decreased metabolism of Imatinib caused by Methamphetamine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [153]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Imatinib caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [241]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Imatinib caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [242]
Istradefylline DM20VSK Moderate Decreased metabolism of Imatinib caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [148]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Imatinib caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [243]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Imatinib caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [148]
Abametapir DM2RX0I Moderate Decreased metabolism of Imatinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [244]
Lefamulin DME6G97 Moderate Decreased metabolism of Imatinib caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [245]
Prednisone DM2HG4X Moderate Decreased metabolism of Imatinib caused by Prednisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [148]
Hydrocortisone DMGEMB7 Moderate Decreased metabolism of Imatinib caused by Hydrocortisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [148]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Imatinib caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [246]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Imatinib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [247]
Enzalutamide DMGL19D Major Increased metabolism of Imatinib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [155]
Darolutamide DMV7YFT Moderate Decreased clearance of Imatinib due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [248]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Imatinib caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [249]
Silodosin DMJSBT6 Moderate Decreased metabolism of Imatinib caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [250]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Imatinib caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [251]
Levomepromazine DMIKFEL Moderate Decreased metabolism of Imatinib caused by Levomepromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [148]
Fluphenazine DMIT8LX Moderate Decreased metabolism of Imatinib caused by Fluphenazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [148]
Axitinib DMGVH6N Moderate Decreased metabolism of Imatinib caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [150]
Temsirolimus DMS104F Moderate Decreased metabolism of Imatinib caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [252]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Imatinib and Canakinumab. Rheumatoid arthritis [FA20] [253]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Imatinib and Rilonacept. Rheumatoid arthritis [FA20] [253]
Dexamethasone DMMWZET Moderate Increased metabolism of Imatinib caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [155]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Imatinib and Leflunomide. Rheumatoid arthritis [FA20] [205]
Oxamniquine DM2QDX1 Moderate Decreased metabolism of Imatinib caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [148]
Quetiapine DM1N62C Moderate Decreased metabolism of Imatinib caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [254]
Mesoridazine DM2ZGAN Moderate Decreased metabolism of Imatinib caused by Mesoridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [148]
Thioridazine DM35M8J Major Decreased metabolism of Imatinib caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [255]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Imatinib caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [256]
Perphenazine DMA4MRX Moderate Decreased metabolism of Imatinib caused by Perphenazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [148]
Risperidone DMN6DXL Moderate Decreased metabolism of Imatinib caused by Risperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [148]
Fentanyl DM8WAHT Major Decreased metabolism of Imatinib caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [153]
Sufentanil DMU7YEL Moderate Decreased metabolism of Imatinib caused by Sufentanil mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [148]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Imatinib when combined with Anthrax vaccine. Sepsis [1G40-1G41] [257]
Avanafil DM75CXN Major Decreased metabolism of Imatinib caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [258]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Imatinib caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [259]
Vardenafil DMTBGW8 Moderate Decreased metabolism of Imatinib caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [260]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Imatinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [148]
Tedizolid DMG2SKR Moderate Decreased clearance of Imatinib due to the transporter inhibition by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [150]
LDE225 DMM9F25 Major Decreased metabolism of Imatinib caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [261]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Imatinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [150]
Larotrectinib DM26CQR Moderate Decreased metabolism of Imatinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [153]
Methylprednisolone DM4BDON Moderate Decreased metabolism of Imatinib caused by Methylprednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [148]
Ifosfamide DMCT3I8 Moderate Decreased metabolism of Imatinib caused by Ifosfamide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [148]
Docetaxel DMDI269 Moderate Decreased metabolism of Imatinib caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [262]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [150]
Armodafinil DMGB035 Minor Decreased metabolism of Imatinib caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [153]
LEE011 DMMX75K Moderate Decreased metabolism of Imatinib caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [148]
Etoposide DMNH3PG Moderate Decreased metabolism of Imatinib caused by Etoposide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [148]
Prednisolone DMQ8FR2 Moderate Decreased metabolism of Imatinib caused by Prednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [148]
Norethindrone DMTY169 Moderate Decreased metabolism of Imatinib caused by Norethindrone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [153]
Taxol DMUOT9V Moderate Decreased metabolism of Imatinib caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [263]
Doxorubicin DMVP5YE Moderate Decreased metabolism of Imatinib caused by Doxorubicin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [148]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Imatinib caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [150]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Imatinib and Naltrexone. Substance abuse [6C40] [264]
Warfarin DMJYCVW Major Decreased metabolism of Imatinib caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [178]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Imatinib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [265]
Eltrombopag DMOGFIX Moderate Decreased clearance of Imatinib due to the transporter inhibition by Eltrombopag. Thrombocytopenia [3B64] [266]
As-1670542 DMV05SW Major Decreased metabolism of Imatinib caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [267]
Apixaban DM89JLN Moderate Decreased metabolism of Imatinib caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [150]
Brilinta DMBR01X Moderate Decreased metabolism of Imatinib caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [150]
Cabozantinib DMIYDT4 Moderate Decreased metabolism of Imatinib caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [268]
Sirolimus DMGW1ID Moderate Decreased metabolism of Imatinib caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [148]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Imatinib and Azathioprine. Transplant rejection [NE84] [153]
Tacrolimus DMZ7XNQ Moderate Decreased metabolism of Imatinib caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [148]
Tolbutamide DM02AWV Moderate Decreased metabolism of Imatinib caused by Tolbutamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [148]
Saxagliptin DMGXENV Moderate Decreased metabolism of Imatinib caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [150]
Elagolix DMB2C0E Moderate Increased metabolism of Imatinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [155]
Astemizole DM2HN6Q Moderate Decreased metabolism of Imatinib caused by Astemizole mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [148]
Triamcinolone DM98IXF Moderate Decreased metabolism of Imatinib caused by Triamcinolone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [148]
Fluticasone DMGCSVF Moderate Decreased metabolism of Imatinib caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [153]
Propafenone DMPIBJK Moderate Decreased metabolism of Imatinib caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [148]
Flecainide DMSQDLE Moderate Decreased metabolism of Imatinib caused by Flecainide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [148]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Imatinib caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [148]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Imatinib and Ganciclovir. Virus infection [1A24-1D9Z] [153]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Imatinib and Valganciclovir. Virus infection [1A24-1D9Z] [153]
⏷ Show the Full List of 286 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Imatinib 100 mg tablet 100 mg Oral Tablet Oral
Imatinib 400 mg tablet 400 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006806)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
4 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
5 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
6 BDDCS applied to over 900 drugs
7 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
8 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
11 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
12 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
13 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
14 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
15 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
19 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
20 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
21 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
22 Drug Interactions Flockhart Table
23 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
24 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
25 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
26 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
27 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
28 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
29 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
30 Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
31 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
32 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
33 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
34 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
35 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
36 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
37 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
38 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
39 Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
40 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
41 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
42 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
43 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
44 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
45 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
46 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
47 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
48 Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
49 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
50 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
51 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
52 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
53 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
54 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
55 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
56 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
57 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
58 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
59 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
60 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
61 Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
62 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
63 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
64 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
65 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
66 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
67 Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
68 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
69 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
70 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
71 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
72 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
73 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
74 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
75 In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50(3):209-15.
76 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
77 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
78 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
79 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
80 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
81 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
82 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
83 Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
84 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
85 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
86 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
87 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
88 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
89 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
90 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
91 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
92 Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
93 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
94 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
95 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
96 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
97 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
98 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
99 FDA Drug Development and Drug Interactions
100 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
101 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
102 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
103 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
104 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
105 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
106 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
107 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
108 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
109 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
110 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
111 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
112 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
113 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
114 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
115 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
116 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
117 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
118 Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
119 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
120 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
121 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
122 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
123 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
124 Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
125 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
126 Danusertib, an aurora kinase inhibitor.Expert Opin Investig Drugs.2012 Mar;21(3):383-93.
127 ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125.
128 Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326.
129 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
130 Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78.
131 Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019 Oct 26;9:88.
132 NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. Front Biosci (Elite Ed). 2011 Jun 1;3:1273-88.
133 Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002 Jan 15;99(2):664-71.
134 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
135 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
136 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
137 Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.
138 National Cancer Institute Drug Dictionary (drug id 695817).
139 Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
140 Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9.
141 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
142 New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
143 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
144 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
145 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
146 National Cancer Institute Drug Dictionary (drug id 452042).
147 Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
148 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
149 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
150 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
151 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
152 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
153 Cerner Multum, Inc. "Australian Product Information.".
154 Adamson PC "Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia." Semin Hematol 31 (1994): 14-7. [PMID: 7831580]
155 Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865]
156 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
157 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
158 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
159 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
160 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
161 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
162 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
163 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
164 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
165 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
166 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
167 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
168 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
169 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
170 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
171 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
172 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
173 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
174 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
175 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
176 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
177 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
178 Canadian Pharmacists Association.
179 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
180 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
181 Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
182 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
183 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
184 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
185 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
186 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
187 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
188 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
189 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
190 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
191 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
192 Dutreix C, Peng B, Mehring G, et al. "Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects." Cancer Chemother Pharmacol 54 (2004): 290-4. [PMID: 15138710]
193 Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M "Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes." Eur J Clin Pharmacol 57 (2001): 709-15. [PMID: 11829200]
194 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
195 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
196 Product Information. Inspra (eplerenone). Searle, Chicago, IL.
197 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
198 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
199 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
200 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
201 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
202 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
203 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
204 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
205 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
206 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
207 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
208 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
209 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
210 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
211 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
212 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
213 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
214 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
215 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
216 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
217 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
218 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
219 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
220 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
221 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
222 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
223 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
224 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
225 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
226 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
227 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
228 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
229 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
230 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
231 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
232 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
233 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
234 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
235 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
236 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
237 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
238 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
239 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
240 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
241 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
242 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
243 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
244 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
245 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
246 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
247 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
248 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
249 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
250 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
251 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
252 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
253 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
254 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
255 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
256 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
257 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
258 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
259 Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
260 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
261 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
262 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
263 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
264 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
265 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
266 Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]
267 Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]
268 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.